Biontech Se

Biontech Rna Pharmaceuticals Gmbh

Biontech Ag

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Universitãt Stuttgart

Other

Tron

Biontech Rna Pharmaceuticals Gbmh

Tron-Translationale Onkologie An Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Ggmbh

Biotech Rna Pharmaceuticals Gmbh

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Gemeinnuzige Gmbh

Johannes Gutenberg-Universität Mainz

Tron Translationale Onkologie an Der Universitaetsmedizin Der Johannes Gutenberg-universitaet Mainz Ggmbh

Sebastian Kreiter

Ugur Sahin

Mustafa Diken

Heinrich Haas

Yves Hüsemann

Kerstin Reuter

Özlem Türeci

Kerstin Walzer

Hossam Hefesha

Ozlem Tureci

Friederike Gieseke

Lena Mareen Kranz

Silke Holtkamp

Michael Koslowski

Roland Kontermann

Klaus Pfizenmaier

Tana Omokoko

Martin Löwer

Sebastian Hörner

Annette Vogel

Jan Diekmann

John Christopher Castle

Anne Schlegel

Martin Meng

Dafne Müller

Daniel Fritz

Ronald Backer

Johannes Hendrikus De Graaf

Bernhard Renard

Cedrik Britten

Stephanie Erbar

Yves Husemann

Oezlem Tuereci

Thorsten Klamp

Sebastian Boegel

Barbara Schrörs

Mathias Vormehr

Arbel David Tadmor

Sina Fellermeier

Phillip Heller

Jorge Herrero Moreno

Jutta Petschenka

Christina Krienke

Abderraouf Selmi

Hossam Hefresha

Daniel Zucker

Sina Fellermaier

Jorge Moreno Herrero

Arbel D Tadmor

Martin Lower

Dafne Muller

It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

Modification of RNA, producing an increased transcript stability and translation efficiency

The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.

Formulation for administration of RNA

The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

RNA for treatment of autoimmune diseases

The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

Particles comprising a shell with RNA

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

RNA formulation for immunotherapy

The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.

Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell

The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.

The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

Recombinant vaccines and use thereof

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

Individualized vaccines for cancer

The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

Predicting T cell epitopes useful for vaccination

The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.

Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands

The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.

RNA molecules encoding cytokine fusion proteins and methods of use thereof

Growing community of inventors

Mainz, Germany

Sebastian Kreiter